TO COMPARE THE ROLE OF CALCIPOTRIOL ALONE VERSUS COMBINATION WITH BETAMETHASONE IN MILD TO MODERATE PSORIASIS

Abstract

Background: Calcipotriol is a vitamin D analogue is now a day has been used as monotherapy in mild to moderate Psoriasis as daily application. We conducted an open label comparative study to assess the efficacy of calcipotriol local application as monotherapy v/s the Calcipotriol plus Betamethasone combination to observe any significant change. Aim: To Assess the efficacy of Calcipotriol in combination with Betamethasone and alone in mild to moderate psoriasis. Methods and Materials: The Psoriatic Patients (mild to moderate) were enrolled (60) and divided into two groups received Calcipotriol (Group-A) and Calcipotriol and Betamethasone (Group -B) for three months. At the end of study period the parameter (PASI) scores was examined for any change. Results: The significant change in ± SEAM values for the period from day 0- 90 in group -A seen (Calcipotriol) v/s group -B (Calcipotriol plus Betamethasone).A reduction of 67.89% in PASI, while 81.49% in group -B. The results of both groups are highly significant (P < 0.001). Conclusion: Calcipotriol in combination with Betamethasone is superior to as monotherapy in terms of efficacy and safety